Factors associated with improved glycemic control following continuous subcutaneous insulin infusion therapy in patients with type 2 diabetes uncontrolled with bolus‐basal insulin regimens: An analysis from the OpT2mise randomized trial. Issue 10 (25th July 2017)

• Record Type: Journal Article
• Authors: Metzger, Muriel; Castañeda, Javier; Reznik, Yves; Giorgino, Francesco; Conget, Ignacio; Aronson, Ronnie; de Portu, Simona; Runzis, Sarah; Lee, Scott W.; Cohen, Ohad
• Is Part Of: Diabetes, obesity & metabolism. Volume 19:Issue 10(2017)
• Page Start: 1490
• Page End: 1494
• Publication Date: 2017-07-25
• Subjects: blood glucose self‐monitoring -- glycated hemoglobin -- insulin infusion systems -- insulin therapy -- multiple daily injections -- type 2 diabetes mellitus; Diabetes -- Periodicals; Obesity -- Periodicals; Metabolism -- Disorders -- Periodicals; Clinical pharmacology -- Periodicals; 616.462
• DOI: 10.1111/dom.12960
• Languages: English
• ISSNs: 1462-8902

Abstract

Abstract : This analysis investigated factors associated with the decrease in HbA1c in patients receiving continuous subcutaneous insulin infusion (CSII) in the OpT2mise randomized trial. In this study, patients with type 2 diabetes and HbA1c >8% following multiple daily injections (MDI) optimization were randomized to receive CSII ( n = 168) or MDI ( n = 163) for 6 months. Patient‐related and treatment‐related factors associated with decreased HbA1c in the CSII arm were identified by univariate and multivariate analyses. CSII produced a significantly greater reduction in HbA1c than MDI, and the treatment difference increased with baseline HbA1c. In the CSII arm, the only factors significantly associated with decreased HbA1c were higher baseline HbA1c ( P < .001), geographical region ( P < .001), higher educational level ( P = .012), higher total cholesterol level ( P = .002), lower variability of baseline glucose values on continuous glucose monitoring ( P < .001) and the decrease in average fasting self‐monitored blood glucose at 6 months ( P < .001). These findings suggest that CSII offers an option to improve glycemic control in a broad range of patients with type 2 diabetes in whom control cannot be achieved with MDI. OpT2miseClinicalTrials.gov number: NCT01182493 (https://clinicaltrials.gov/ ).